OTC MONOGRAPH DEVELOPMENT IS ABOUT 30% OF FDA OTC OFFICE WORKLOAD
This article was originally published in The Tan Sheet
Executive Summary
OTC MONOGRAPH DEVELOPMENT IS ABOUT 30% OF FDA OTC OFFICE WORKLOAD, OTC Drug Evaluation Director Michael Weintraub, MD, asserted at a May 24 forum on Rx-to-OTC switches sponsored by Tufts University. Weintraub estimated that approximately 21% of the OTC office resources are taken up by monograph maintenance, 8% by Rx-to-over-the-counter switch applications, 14% by meetings with OTC manufacturers and 5% by congressional inquiries.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning